Objective: To assess the efficacy of hypofractionated linac-based stereotactic radiotherapy with a micro-multileaf collimator (mMLC) in lung cancer patients with brain metastases. Methods: Seventy-eight lesions of brain metastases in 49 lung cancer patients treated by stereotactic radiotherapy between September 2003 and December 2006 were analyzed. In the treatment planning, the planning target volume (PTV) was defined as an enhanced lesion plus 3 mm margin. A total dose of 39-42 Gy in three fractions was delivered to the isocenters of the PTV. Results: The median survival time after stereotactic radiotherapy was 17.4 months. The 1-and 2-year survival rates were 61% and 32%, respectively. The presence of extracranial tumors, the pre-treatment performance status, and the Radiation Therapy Oncology Group recursive partitioning analysis class were significant prognostic factors. The 1-and 2-year local recurrence rates were 14% and 17%, respectively, with no serious acute toxic effect. Injuries involving brain necrosis were observed in six patients. New brain metastases or meningeal carcinomatosis was seen in more than half of the patients following treatment with stereotactic radiotherapy. Conclusions: Hypofactionated stereotactic radiotherapy with mMLC is considered to be an effective and safe modality for the treatment of brain metastases in lung cancer patients.
INTRODUCTION
The incidence of metastatic brain tumors has been increasing accompanied with an increase of patients with malignant tumors and the influence of prolonged in prognosis due to improvements in cancer treatment. Treatment for patients with brain metastases has been evolving. In addition to surgical resection or whole brain radiation therapy (WBRT), stereotactic irradiation (STI) is an important treatment method for limited intracranial metastases (1 -4) . STI administers a high radiation dose concentrated to the tumor from multiple fields. It is called stereotactic radiosurgery (SRS) when treating a single fraction or stereotactic radiation therapy (SRT) when treating multiple fractions.
Gamma-knife is often used for the treatment of brain tumors by means of SRS, and a micro-multileaf collimator (mMLC) attached to the linear accelerator can be used when these lesions are treated by SRT. The 1-year local control rates of SRS alone have been reported to range from 60% to 90% (1, 2, 5) . The therapeutic ratio can be elevated by fractionated SRT without the increase of late radiation injury, but the optimal dose or schedule of fractionation has not yet been standardized.
Brain metastasis is the one of the most common problems in the management of lung cancer patients. More than half of the patients treated with SRT are lung cancer patients in this hospital, and patients with lung primary have a better prognosis in comparison to those with other primary sites. This communication presents a retrospective analysis of the treatment results of hypofractionated linac-based SRT with mMLC for lung cancer patients with brain metastases.
PATIENTS AND METHODS

PATIENTS
The primary selection criteria for SRT with mMLC for brain metastases were: (i) patients with three or fewer brain metastases, (ii) Karnofsky performance status (KPS) score of 70, (iii) no findings of meningitis carcinomatosa, and (iv) tolerance to fixation during the planning or treatment time. Patients with records of irradiation to the brain before SRT were excluded from the analysis of this study.
From September 2003 to December 2006, 49 lung cancer patients with 78 lesions of brain metastases were treated by linac-based SRT with mMLC at Saitama Cancer Center. The patients' age ranged from 40 to 82 years with a median of 67 years. Thirty-four patients were males and 15 were females. All patients had histological evidence of primary lung cancer. The histological types of primary lesions were 36 cases of adenocarcinoma, 6 of squamous cell carcinoma, 3 of small cell carcinoma, 3 of large cell carcinoma and 1 of adenosquamous cell carcinoma. Application of Radiation Therapy Oncology Group recursive partitioning analysis (RTOG-RPA) for brain metastases revealed that 6 patients fitted the criteria for Class I, 42 for Class II and 1 for Class III (6) . All patients were evaluated by magnetic resonance imaging (MRI) before SRT. The numbers of brain metastases were one in 25 patients, two in 19 and three in 5. The greatest dimensions of tumors ranged from 4 to 38 mm with a median of 12 mm. Sixty-two lesions were 20 mm, 10 were 21-30 mm and 6 lesions were .30 mm.
TREATMENT
The planning and treatment of SRT was carried out using a commercially available radiation treatment system, Accuknife (DiREX). This system is composed of mMLC (AccuLeaf ) with a treatment planning software (AccuSoft WB 2.101). The AccuLeaf has 96 tungsten leaves (48 pairs) in two perpendicular layers and enables shaping a linear accelerator beam to a desired aperture according to tumor shape with a high spatial resolution of 2.7 mm. These devices are operated in conjunction with a linear accelerator (Clinac 21EX, Varian). HeadFix (Medical Intelligence) was used to secure head immobilization. The HeadFix system uses a mouthpiece and a patient-specific dental mold with the patient's upper palate impression and solid vacuum bonding with the hard palate, precisely and non-invasively positioning within 2 mm errors. After the head was immobilized in the mold, contrast-enhanced computed tomographic (CT) scans were taken through the entire brain with 2.5 mm slice thickness for the treatment planning. If required, MRI scans for the fusion planning were performed under the same conditions. The images were transferred to online treatment planning system. Targets were defined as follows: the gross tumor volume (GTV) consisted of the enhanced gross disease. The clinical target volume was considered to be equivalent to the GTV with no additional margin. The planning target volume (PTV) provided an additional margin of 3 mm in all directions in consideration of reproducibility in fixation. Isocenter of the beams was set up as the center of PTV. Repeated CT examinations were carried out during the course of SRT to verify the treatment setup errors, which were found to be within 2 mm. Treatment plans were designed using 6 -12 static non-coplanar beams of 6 MV photons. PTV was always enclosed by the 90% isodose area. During the first 12 months, the dose prescribed to the isocenter was 13 Gy per fraction, and the total dose of 39 Gy in three fractions was administered over 3 straight days. The prescribed dose was escalated to 14 Gy per fraction, and the total dose of 42 Gy in three fractions was delivered in patients treated since latter half of 2004. If the brainstem was near to PTV, the irradiation dose to brainstem was planned not to exceed a single dose of 7 Gy. Among the 78 lesions, 24 lesions were treated by a total dose of 39 Gy and 54 were treated by a total dose of 42 Gy.
TREATMENT EVALUATION
The patients were evaluated by MRI at 1-and 3-month intervals following treatment. Response evaluation was based on the World Health Organization (WHO) criteria. The tumor response was assessed by measurement of enhanced lesions in T1-weighted image with contrast-enhanced agent.
STATISTICS
All statistical analyses were performed with commercial statistical software (StatView 5.0, SAS Institute Inc.). The survival time was measured from the first day of SRT to the date of death or last follow-up time. The Kaplan -Meier method was employed to determine the actuarial survival rate or local recurrence rate. Prognostic factors were examined with the log-rank test.
RESULTS
SURVIVAL AND RESPONSE
The follow-up duration of all patients ranged from 0.4 to 60.5 months. The median follow-up time of all patients was 17.4 months. In addition, eight cases were alive at the time of the last follow-up. The median follow-up time of the eight surviving patients was 31.5 months. Almost all of the patients were followed, and the 2-year follow-up rate after SRT was 98%. The Kaplan -Meier survival curve after SRT is shown in Fig. 1 . The median survival time (MST) for the entire group was 17.4 months from the time of SRT. The actuarial 1-and 2-year overall survival rates were 61% and
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SRT with mMLC to treat brain metastases of lung cancer Follow-up imaging was available for 69 of the 78 lesions to determine local control. Twenty-one lesions achieved a complete response (CR) and 37 a partial response, for an overall response rate of 84%. Four lesions showed a response of progressive disease and seven showed stable disease. No in-field recurrence was seen in the lesions that achieved CR during the observation time. Finally, nine lesions in six patients failed to achieve local control after SRT.
The actuarial in-field recurrence rate is shown in Fig. 2 . One-and 2-year local recurrence rates were 11% and 21% in lesions treated with a total dose of 39 Gy, and 17% and 17% in lesions treated by a total dose of 42 Gy, respectively (P ¼ 0.80). The relationships between the tumor sizes and local control rates were examined by partitioning due to the tumor size of 15, 20, or 30 mm, but no significant difference was seen (P ¼ 0.97, 0.13 and 0.18, respectively).
TOXIC EFFECTS
All patients completed SRT following the planned schedule without experiencing any immediate or acute symptoms. Six patients with six lesions exhibited the findings of radiation necrosis on follow-up MRI. These late complications occurred 9 -26 months after SRT. All six lesions had been treated with a total dose of 42 Gy in three fractions. One of these patients underwent a surgical resection and the pathological finding was necrosis without evidence of recurrence (Fig. 3) . Five other patients were followed by using steroids, but severe neurological toxicity was not seen greater than Grade 3 in Common Terminology Criteria for Adverse Events v3.0.
POST-TREATMENT
No protocol has yet been established regarding the treatment after the completion of SRT. Some cases received chemotherapy, and others were just followed up. New metastatic lesions or meningeal dissemination was seen in 30 of 49 Figure 1 . Survival from the time of stereotactic radiotherapy treatment. 
DISCUSSION
Brain metastases are generally associated with a poor prognosis. According to the analysis of randomized clinical trials by RTOG, the MST of patients with brain metastases after whole brain irradiation was 4 -6 months, and the major cause of death was attributable to uncontrolled brain metastases in 30 -50% of treated patients (6 -8) . The prognosis of patients with brain metastases is often limited due to the status of extracranial tumors. However, a relatively long-term survival may be achieved in some cases, especially in those where the extracranial lesions can be controlled, so it is important to try to improve the local control to avoid death due to brain tumors. In the present study, the median survival of lung cancer patients with brain metastases after SRT was 17.4 months, with an actuarial 1-year survival rate of 61%. The overall response rate was 84%, and the 1-and 2-year local recurrence rates were 14% and 17%, respectively. The effect of chemotherapy or selection of patients has a large influence on the extension of the survival time, but these results cannot be achieved without the local control of brain metastases. STI administers a high radiation dose concentrated to the lesion from multiple fields. The efficacy of SRS and the relationship between local tumor control and the radiation dose have been reported (1, 2) . Fractionated SRT can elevate the therapeutic ratio by dose escalation without causing any late radiation injury. The previous studies of SRT for brain tumors with various doses and fractionations are summarized in Table 2 (3,4,9 -13 ). The optimal dose or schedule of fractionation has not yet been standardized, and there are few reports describing the treatment rationale of SRT for metastatic brain tumors. Before this series, we initially examined the feasibility of SRT with a total dose of 36 -40 Gy in four fractions for some patients with brain metastases, and confirmed the early tumor response without any toxic effects. Thereafter, the treatment was planned in three fractions over 3 straight days for convenience on a parity with SRS. We have therefore administered a total dose of 39 Gy in three fractions since September 2003, and no serious adverse effects were seen in this prescription. Thereafter, the prescribed dose was escalated into a total dose of 42 Gy in three fractions to improve the local control. The actuarial 2-year local recurrent rates were 21% in patients treated with a total dose of 39 Gy and 17% in patients irradiated 42 Gy, and no significant difference was seen. Compared with the previous reports of SRT, these administered doses were relatively high and the total treatment period was also shorter (3,4,9 -13) . As a result, a high local control was achieved in this series and the adverse events were all considered to be at acceptable levels. The occurrence of radiation necrosis was seen in six patients who were treated with a total dose of 42 Gy. Figure 3 shows the MRI findings of pathologically confirmed brain necrosis and the fusion image of MRI with the dose distribution map at the time of treatment of SRT. The enhanced area seems to be related to the 95% isodose line (a total dose of 39.9 Gy), and peripheral edema expanded to over the 50% isodose line. The damage did not become lethal in these patients, but re-consideration of the dose prescription might be needed. The local control or adverse effects might be underestimated because of the limited observation periods among patients with metastatic brain tumors. However, it was important to avoid neurological deaths and clinical symptoms. Metastatic brain tumors often present with round images, but some lesions grow to irregular shapes. SRT with mMLC 
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SRT with mMLC to treat brain metastases of lung cancer allows treatment plans to be designed with high dose convergence and homogenous dose distribution for convex or elliptical targets. It took 15 -30 min for the treatment of each lesion with minor adverse event, so the treatment could be performed during an outpatient visit for asymptomatic patients.
High local control was achieved in this study of treatment with SRT only, but findings of new brain metastases or meningeal carcinomatosis were seen in more than half of patients. Randomized trials addressing the efficacy of a combination of SRS and WBRT have been reported (5, 14) . Local control is obviously improved with a combination of SRS and WBRT in both reports, but an increased survival benefit was seen in limited cases with relatively good conditions. The optimal doses of SRS and WBRT and the indications of treatments should still be discussed.
CONCLUSION
Treatment efficacy of SRT with mMLC with non-invasive immobilization was confirmed. High local control as well as survival rates were achieved in selected patients treated with hypofractionated SRT. The MST after SRT was 17.4 months. The 1-and 2-year survival rates were 61% and 32%, respectively. The 1-and 2-year local recurrence rates were 14% and 17%, respectively, with no serious toxic effects. After the treatment, findings of new brain metastases or meningeal carcinomatosis were seen in more than half of all patients, so the optimal consolidation therapy after SRT remains to be elucidated.
